223 related articles for article (PubMed ID: 28472307)
1. Antiretroviral-treated HIV-1 patients can harbour resistant viruses in CSF despite an undetectable viral load in plasma.
Soulie C; Grudé M; Descamps D; Amiel C; Morand-Joubert L; Raymond S; Pallier C; Bellecave P; Reigadas S; Trabaud MA; Delaugerre C; Montes B; Barin F; Ferré V; Jeulin H; Alloui C; Yerly S; Signori-Schmuck A; Guigon A; Fafi-Kremer S; Haïm-Boukobza S; Mirand A; Maillard A; Vallet S; Roussel C; Assoumou L; Calvez V; Flandre P; Marcelin AG;
J Antimicrob Chemother; 2017 Aug; 72(8):2351-2354. PubMed ID: 28472307
[TBL] [Abstract][Full Text] [Related]
2. Baseline resistance and virological outcome in patients with virological failure who start a regimen containing abacavir: EuroSIDA study.
Cabrera C; Cozzi-Lepri A; Phillips AN; Loveday C; Kirk O; Ait-Khaled M; Reiss P; Kjaer J; Ledergerber B; Lundgren JD; Clotet B; Ruiz L;
Antivir Ther; 2004 Oct; 9(5):787-800. PubMed ID: 15535417
[TBL] [Abstract][Full Text] [Related]
3. Genotypic resistance profiles of HIV-2-treated patients in West Africa.
Charpentier C; Eholié S; Anglaret X; Bertine M; Rouzioux C; Avettand-Fenoël V; Messou E; Minga A; Damond F; Plantier JC; Dabis F; Peytavin G; Brun-Vézinet F; Ekouevi DK;
AIDS; 2014 May; 28(8):1161-9. PubMed ID: 24583671
[TBL] [Abstract][Full Text] [Related]
4. Asymptomatic Cerebrospinal Fluid HIV-1 Viral Blips and Viral Escape During Antiretroviral Therapy: A Longitudinal Study.
Edén A; Nilsson S; Hagberg L; Fuchs D; Zetterberg H; Svennerholm B; Gisslén M
J Infect Dis; 2016 Dec; 214(12):1822-1825. PubMed ID: 27683820
[TBL] [Abstract][Full Text] [Related]
5. Effect of genotypic resistance on the virological response to highly active antiretroviral therapy in cerebrospinal fluid.
Cinque P; Presi S; Bestetti A; Pierotti C; Racca S; Boeri E; Morelli P; Carrera P; Ferrari M; Lazzarin A
AIDS Res Hum Retroviruses; 2001 Mar; 17(5):377-83. PubMed ID: 11282006
[TBL] [Abstract][Full Text] [Related]
6. Prevalence of HIV-1 drug resistance among patients failing first-line ART in Monrovia, Liberia: a cross-sectional study.
Loubet P; Charpentier C; Visseaux B; Borbor A; Nuta C; Adu E; Chapplain JM; Baysah M; Tattevin P; Yazdanpanah Y; Descamps D
J Antimicrob Chemother; 2015; 70(6):1881-4. PubMed ID: 25698771
[TBL] [Abstract][Full Text] [Related]
7. Higher CNS penetration-effectiveness of long-term combination antiretroviral therapy is associated with better HIV-1 viral suppression in cerebrospinal fluid.
Cusini A; Vernazza PL; Yerly S; Decosterd LA; Ledergerber B; Fux CA; Rohrbach J; Widmer N; Hirschel B; Gaudenz R; Cavassini M; Klimkait T; Zenger F; Gutmann C; Opravil M; Günthard HF;
J Acquir Immune Defic Syndr; 2013 Jan; 62(1):28-35. PubMed ID: 23018371
[TBL] [Abstract][Full Text] [Related]
8. Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy.
Canestri A; Lescure FX; Jaureguiberry S; Moulignier A; Amiel C; Marcelin AG; Peytavin G; Tubiana R; Pialoux G; Katlama C
Clin Infect Dis; 2010 Mar; 50(5):773-8. PubMed ID: 20100092
[TBL] [Abstract][Full Text] [Related]
9. [Clinical and virological correlation between the cerebrospinal fluid and blood of HIV-infected children].
Sáez-Llorens X; Castrejón de Wong MC; Castaño E; de Suman O; Báez de Ulloa C; Redondo W; Espino M
Rev Med Panama; 2001; 26():13-8. PubMed ID: 16161718
[TBL] [Abstract][Full Text] [Related]
10. The use of drug resistance algorithms and genotypic inhibitory quotient in prediction of lopinavir-ritonavir treatment response in human immunodeficiency virus type 1 protease inhibitor-experienced patients.
Maillard A; Chapplain JM; Tribut O; Bentué-Ferrer D; Tattevin P; Arvieux C; Michelet C; Ruffault A
J Clin Virol; 2007 Feb; 38(2):131-8. PubMed ID: 17208042
[TBL] [Abstract][Full Text] [Related]
11. High level of HIV-1 resistance in patients failing long-term first-line antiretroviral therapy in Mali.
Fofana DB; Soulié C; Baldé A; Lambert-Niclot S; Sylla M; Ait-Arkoub Z; Diallo F; Sangaré B; Cissé M; Maïga IA; Fourati S; Koita O; Calvez V; Marcelin AG; Maïga AI
J Antimicrob Chemother; 2014 Sep; 69(9):2531-5. PubMed ID: 24855120
[TBL] [Abstract][Full Text] [Related]
12. The significance of low-level plasma HIV viral load on COBAS TaqMan HIV-1 assays for patients with undetectable plasma viral load on COBAS Amplicor monitor version 1.5.
Manavi K
HIV Clin Trials; 2008; 9(4):283-6. PubMed ID: 18753122
[TBL] [Abstract][Full Text] [Related]
13. Discordant CSF/plasma HIV-1 RNA in individuals on virologically suppressive antiretroviral therapy in Western India.
Dravid AN; Natrajan K; Kulkarni MM; Saraf CK; Mahajan US; Kore SD; Rathod NM; Mahajan US; Wadia RS
Medicine (Baltimore); 2018 Feb; 97(8):e9969. PubMed ID: 29465595
[TBL] [Abstract][Full Text] [Related]
14. Construction, training and clinical validation of an interpretation system for genotypic HIV-1 drug resistance based on fuzzy rules revised by virological outcomes.
De Luca A; Vendittelli M; Baldini F; Di Giambenedetto S; Trotta MP; Cingolani A; Bacarelli A; Gori C; Perno CF; Antinori A; Ulivi G
Antivir Ther; 2004 Aug; 9(4):583-93. PubMed ID: 15456090
[TBL] [Abstract][Full Text] [Related]
15. Human Immunodeficiency Virus Type 1 RNA Detected in the Central Nervous System (CNS) After Years of Suppressive Antiretroviral Therapy Can Originate from a Replicating CNS Reservoir or Clonally Expanded Cells.
Joseph SB; Kincer LP; Bowman NM; Evans C; Vinikoor MJ; Lippincott CK; Gisslén M; Spudich S; Menezes P; Robertson K; Archin N; Kashuba A; Eron JJ; Price RW; Swanstrom R
Clin Infect Dis; 2019 Sep; 69(8):1345-1352. PubMed ID: 30561541
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of HIV-1 drug resistance in treated patients with viral load >50 copies/mL: a 2014 French nationwide study.
Assoumou L; Charpentier C; Recordon-Pinson P; Grudé M; Pallier C; Morand-Joubert L; Fafi-Kremer S; Krivine A; Montes B; Ferré V; Bouvier-Alias M; Plantier JC; Izopet J; Trabaud MA; Yerly S; Dufayard J; Alloui C; Courdavault L; Le Guillou-Guillemette H; Maillard A; Amiel C; Vabret A; Roussel C; Vallet S; Guinard J; Mirand A; Beby-Defaux A; Barin F; Allardet-Servent A; Ait-Namane R; Wirden M; Delaugerre C; Calvez V; Chaix ML; Descamps D; Reigadas S;
J Antimicrob Chemother; 2017 Jun; 72(6):1769-1773. PubMed ID: 28333232
[TBL] [Abstract][Full Text] [Related]
17. Diffuse White Matter Signal Abnormalities on Magnetic Resonance Imaging Are Associated With Human Immunodeficiency Virus Type 1 Viral Escape in the Central Nervous System Among Patients With Neurological Symptoms.
Kugathasan R; Collier DA; Haddow LJ; El Bouzidi K; Edwards SG; Cartledge JD; Miller RF; Gupta RK
Clin Infect Dis; 2017 Apr; 64(8):1059-1065. PubMed ID: 28329096
[TBL] [Abstract][Full Text] [Related]
18. Factors associated with cerebrospinal fluid HIV RNA in HIV infected subjects undergoing lumbar puncture examination in a clinical setting.
Rawson T; Muir D; Mackie NE; Garvey LJ; Everitt A; Winston A
J Infect; 2012 Sep; 65(3):239-45. PubMed ID: 22522289
[TBL] [Abstract][Full Text] [Related]
19. Antiviral activity and CSF concentrations of 600/100 mg of darunavir/ritonavir once daily in HIV-1 patients with plasma viral suppression.
Di Yacovo MS; Moltó J; Ferrer E; Curran A; Else L; Gisslén M; Clotet B; Tiraboschi JM; Niubò J; Vila A; Zetterberg H; Back D; Podzamczer D
J Antimicrob Chemother; 2015 May; 70(5):1513-6. PubMed ID: 25608583
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of HIV-1 drug resistance in treated patients with viral load >50 copies/mL in 2009: a French nationwide study.
Assoumou L; Descamps D; Yerly S; Dos Santos G; Marcelin AG; Delaugerre C; Morand-Joubert L; Ruffault A; Izopet J; Plantier JC; Pakianather S; Montes B; Chaix ML; Wirden M; Costagliola D; Masquelier B;
J Antimicrob Chemother; 2013 Jun; 68(6):1400-5. PubMed ID: 23404192
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
